Bimectin Plus, 10/100 Mg/Ml Solution For Injection For Cattle
Revised: June 2015
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Bimectin Plus, 10/100 mg/ml Solution for Injection for Cattle- UK, DK, BE, PT, RO
Bimectin Fluke, 10/100 mg/ml, Solution for Injection for Cattle-DE
Cevamec D,10/100 mg/ml,Solution injectable pour bovins- FR
Renomec Plus, 10/100 mg/ml,Solucion inyectable para bovinos- ES
Maximec Plus, 10/100 mg/ml, Solution for injection for Cattle– PL, IT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Solution for injection
A clear colourless to pale yellow sterile non-aqueous solution
4. CLINICAL PARTICULARS
4.1 Target species
4.2 Indications for use, specifying the target species
The product is indicated for the treatment of mixed trematode and nematode or arthropod infestations of the following parasites:
Gastrointestinal roundworms (adult and fourth-stage larvae):
Ostertagia ostertagi (including inhibited larval stages)
Strongyloides papillosus (adult)
N. spathiger (adult)
N. helvetianus (adult)
Lungworms (adult and fourth-stage larvae)
Liver fluke (adult):
Eye worms (adult):
Warbles (parasitic stages):
Sarcoptes scabiei var. bovis
The product may also be used as an aid in the control of biting lice (Damalinia bovis) and the mange mite Chorioptes bovis, but complete elimination may not occur.
The product given at the recommended dosage of 1ml/50kg bodyweight controls re-infection with Haemonchus placei, Cooperia spp. andTrichostrongylus axei acquired up to 14 days after treatment, Ostertagia ostertagi andOesophagostomum radiatum acquired up to 21 days after treatment and Dictyocaulus viviparus acquired up to 28 days after treatment.
Do not use intramuscularly or intravenously.
This product is a low volume product authorised for use in cattle. It must not be used in other species as severe adverse reactions, including fatalities in dogs, may occur, especially Collies, Old English Sheepdogs and related breeds or crosses.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
4.4 Special warnings for each target species
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to Ivermectin has been reported in Ostertagia ostertagi and Cooperia species in cattle within the EU. Therefore, the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of these helminth species and recommendations on how to limit further selection for resistance to anthelmintics.
4.5 Special precautions for use
Special precautions for use in animals
This product does not contain any antimicrobial preservative. Swab septum before removing each dose.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
Do not smoke or eat whilst handling the product.
Wash hands after use.
Wear gloves and glasses when handling the veterinary medicinal product. Direct contact with the skin should be avoided.
Take care to avoid self-injection: the product may cause local irritation and/or pain at the injection site. In case of accidental self-injection, seek medical advice immediately and show the package leaflet to the physician.
The product is very toxic to aquatic organisms and dung insects. Treated cattle should not have direct access to ponds, streams or ditches for 14 days after treatment. Long term effects on dung insects caused by continuous or repeated use cannot be excluded. Therefore repeat treatments on a pasture within a season should only be given on the advice of a veterinarian.
4.6 Adverse reactions (frequency and seriousness)
Transitory discomfort has been observed in some cattle following subcutaneous administration. A low incidence of soft tissue swelling at the injection site has been observed. These reactions disappeared without treatment.
4.7 Use during pregnancy, lactation or lay
Can be used in pregnancy and lactation.
Can be used in breeding animals.
See section 4.11.
4.8 Interaction with other medicinal products and other forms of interaction
4.9 Amounts to be administered and administration route
Dosage and duration of treatment
ivermectin and 2mg clorsulon per kg bodyweight corresponding to a
single dose of 1ml per 50kg bodyweight.
Method of administration
The product should be administered only by subcutaneous injection under the loose skin in front of or behind the shoulder.
Divide doses in excess of 10 ml between different injection sites and use different sites to those used for other parenteral medications.
A sterile 17 gauge ½ inch (15-20mm) needle is recommended. Replace with a fresh sterile needle after every 10-12 animals or sooner if the needle becomes soiled.
When the temperature of the product is below 5°C, difficulty in administration may be encountered due to increased viscosity. Warming the product and injection equipment to about 15°C will greatly increase the ease with which the product can be injected.
When using the 500ml pack size use only automatic syringe equipment. For the 50ml pack size, use of a multidose syringe is recommended.
The timing of treatment should be based on epidemiological factors and should be customised for each individual farm. A dosing program should be established by a qualified professional person.
To ensure a correct dosage, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.
If animals are to be treated collectively rather than individually, to avoid under- or over-dosing, they should be grouped according to their bodyweight and dosed accordingly.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
A dose of 25ml product per 50kg bodyweight (25 times the recommended dose level) may result in an injection site lesion, including tissue necrosis, oedema, fibrosis and inflammation. No other drug-related reactions have been observed.
4.11 Withdrawal period(s)
Meat and offal: 66 days
Milk: Do not use in cattle producing milk for human consumption.
Do not use in non-lactating dairy cows including pregnant heifers within 60 days of calving.
5. PHARMACOLOGICAL PROPERTIES
ATC vet code: QP54AA51
5.1 Pharmacodynamic properties
Ivermectin is a member of the macrocyclic lactone class of endectocides and has a unique mode of action. It has broad and potent antiparasitic activity. It binds selectively and with high affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to an increase in the permeability of the cell membrane to chloride ions with hyperpolarisation of the nerve or muscle cell, resulting in paralysis and death of the parasite. Compounds of this class may also interact with other ligand-gated chloride channels such as those gated by the neurotransmitter gamma-amino-butyric acid (GABA).
The margin of safety for compounds of this class is attributable to the fact that mammals do not have glutamate-gated chloride channels, that the macrocyclic lactones have a low affinity for other mammalian ligand-gated chloride channels and they do not readily cross the blood-brain barrier.
Clorsulon is rapidly absorbed in the blood stream. It is bound to the erythrocytes and plasma which are ingested by the fluke. Clorsulon inhibits the glycolytic enzymes in the fluke and deprives it of its main source of metabolic energy.
5.2 Pharmacokinetic properties
After subcutaneous administration of 2mg clorsulon and 0.2mg ivermectin per kg bodyweight, the plasma profile demonstrated a slow, steady absorption of ivermectin which reached a maximum plasma concentration at a median time of 1.50 days. In contrast, clorsulon appeared rapidly absorbed with a maximum plasma concentration at a median time of 0.25 days. The terminal half life for the two active ingredients were determined as follows: Ivermectin approximately 3.79 days and Clorsulon approximately 3.58 days
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Monoethanolamine (for pH adjustment)
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.
6.3 Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years
Shelf-life after first opening the immediate packaging: 28 days
6.4. Special precautions for storage
Keep the container in the outer carton in order to protect from light.
6.5 Nature and composition of immediate packaging
Container material: High density polyethylene
Container closure: Siliconised grey bromobutyl rubber stopper with tamper evident aluminium overseal.
Container colour: Natural
Container volume: 50ml, 250ml or 500ml
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
EXTREMELY DANGEROUS TO FISH AND AQUATIC LIFE. Do not contaminate surface waters or ditches with the product or used container. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Cross Vetpharm Group Ltd
8. MARKETING AUTHORISATION NUMBER
9. DATE OF FIRST AUTHORISATION
19 February 2010
10. DATE OF REVISION OF THE TEXT
Approved: 23 June 2015
Page 6 of 6